Related Experiment Video

Updated: Jun 2, 2026

Application of DNA Fingerprinting using the D1S80 Locus in Lab Classes
08:35

Application of DNA Fingerprinting using the D1S80 Locus in Lab Classes

Published on: July 17, 2021

[Association between apolipoprotein A5 gene polymorphism and coronary heart disease in the Han population from

Shan Yuan1, Yi-tong Ma, Xiang Xie

  • 1Key Laboratory of Cardiovascular Disease Research of Xinjiang, Urumqi 830054, China.

Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi
|April 27, 2011
PubMed

Insights

The c.553G>T polymorphism in the apolipoprotein A5 (ApoA5) gene is linked to coronary heart disease (CHD) risk in Xinjiang

Area of Science:

  • Genetics
  • Cardiovascular Disease
  • Biochemistry

Background:

  • Coronary heart disease (CHD) is a leading cause of mortality globally.
  • Genetic factors play a significant role in CHD susceptibility.
  • The apolipoprotein A5 (ApoA5) gene is implicated in lipid metabolism and cardiovascular risk.

Purpose of the Study:

  • To investigate the association between the ApoA5 gene c.553G>T polymorphism and CHD in the Han population of Xinjiang.
  • To examine the influence of serum lipid levels on this association.

Main Methods:

  • Genotyping of the ApoA5 c.553G>T polymorphism using polymerase chain reaction and restriction fragment length polymorphism analysis in 486 CHD patients and 501 controls.
  • Measurement of serum lipid profiles (triglyceride, total cholesterol) in all participants.

Main Results:

  • A significant difference in genotype distribution was observed between CHD patients and controls (P=0.013).
  • Carrying the T allele (TT + GT genotypes) was associated with an increased risk of CHD (OR=1.753, P<0.05), independent of other risk factors.
  • Individuals with the T allele exhibited higher serum triglyceride levels and, in the CHD group, higher total cholesterol levels compared to those with the GG genotype.

Conclusions:

  • The ApoA5 c.553G>T polymorphism influences serum triglyceride and total cholesterol levels in the Xinjiang Han population.
  • This polymorphism is associated with CHD development, with the T allele potentially acting as an independent risk factor.
Abstract

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...